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One major determinant of host tropism for filoviruses is viral glycoprotein (GP), which is involved in receptor binding and viral entry. Compared
to Ebola GP (EGP), Marburg GP (MGP) is less well characterized in viral entry. In this study, using a human immunodeficiency virus-based
pseudotyped virus as a surrogate system, we have characterized the role ofMGP in viral entry. We have shown that like EGP, the mucin-like region of
MGP (289–501) is not essential for virus entry. We have developed a viral entry interference assay for filoviruses, and using this assay, we have
demonstrated that transfection of EGP orMGP in target cells can interfere with EGP/HIVandMGP/HIV pseudotyped virus entry in a dose-dependent
manner. These results are consistent with the notion that Ebola and Marburg viruses use the same or a related host molecule(s) for viral entry.
Substitutions of the non-conserved residues in MGP1 did not impair MGP-mediated viral entry. Unlike that of EGP1, individual substitutions of
many conserved residues ofMGP1 exerted severe defects inMGP expression, incorporation to HIV virions, and thus its ability to mediate viral entry.
These results indicate that MGP is more sensitive to substitutions of the conserved residues, suggesting that MGP may fold differently from EGP.
© 2006 Elsevier Inc. All rights reserved.Keywords: Filovirus glycoprotein; Viral entry; Receptor interference; Ebola virus GP; Marburg virus GP; Receptor binding domainIntroduction
Filovirus family consists of Ebola virus (EBOV) and
Marburg virus (MARV) which can cause severe hemorrhagic
fever in humans and non-human primates with mortality rates up
to 90% (Sanchez et al., 2001). Viral outbreaks are rare and
endemic in central regions of the Africa. EBOV and MARV
outbreaks occur in distinct ecological niches(Feldmann et al.,
2004). EBOV infections usually occur in humid rain forests of
central and western Africa and MARV infections occur in the
drier regions of central and eastern Africa (Feldmann et al.,
2004; Peterson et al., 2004). The mode of transmission of
filoviruses is not known, although fruit bats have been recently
implicated as the natural reservoirs of Ebola virus(Leroy et al.,
2005; Peterson et al., 2004). Several promising vaccination
methods have been developed in non-human primate models,
but currently there is no vaccine or treatment available for⁎ Corresponding author. Fax: +1 312 355 0220.
E-mail address: lijun@uic.edu (L. Rong).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.06.041filovirus infection in human (Jones et al., 2005; Sullivan et al.,
2000, 2003; Xu et al., 1998).
Filoviruses are enveloped, negative-sense, single stranded,
RNA viruses with a genome of approximately 19 kb (Sanchez
et al., 2001). EBOV and MARV share approximately 35%
overall sequence identity (Sanchez et al., 1993). The genome
contains seven genes (NP, VP35, VP40, GP, VP30, VP24, and L)
and it encodes eight proteins in EBOV and seven proteins in
MARV (Sanchez et al., 2001, 1993). In the case of EBOV, the
GP gene encodes two proteins, a secreted form called sGP (80%
of GP transcripts) and a membrane-anchored form called GP
(20% of GP transcripts), produced by transcriptional editing of
the GP mRNA (Sanchez et al., 1996; Volchkov et al., 1995). GP
is involved in receptor binding and virus–host membrane fusion.
GP is synthesized as a single polypeptide (Feldmann et al.,
2001). After the cleavage of the signal peptide, the polypeptide
undergoes glycosylation in the ER to form endoplasmic
precursor pre-GPer containing high mannose type of N-linked
sugars (Jeffers et al., 2002; Volchkov et al., 1998). Pre-GPer is
further processed in the Golgi to give rise to a precursor
Fig. 1. Schematic representations of Marburg and Ebola GP deletion mutants.
Marburg GP and mucin deletion mutants are shown in the top. Ebola GP and
mucin deletion mutants are shown at the bottom.
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Golgi, GP is cleaved by a furin-like protease in two subunits; a
surface subunit GP1 and a transmembrane subunit GP2
(Volchkov et al., 1998). GP1 is linked with GP2 through a
disulfide bond (Jeffers et al., 2002). GP on the surface of virions
is present as a trimer. The GP1 subunit is involved in receptor
binding and the GP2 subunit is involved in fusion of the viral and
host membranes. Several cell surface factors, such as Folate
receptor α, DC-SIGN, L-SIGN, and hMGL have been
implicated in facilitating filovirus entry, but the primary receptor
for mediating entry has not been identified yet (Alvarez et al.,
2002; Chan et al., 2001; Lin et al., 2003; Simmons et al., 2003a,
2003b; Takada et al., 2004). Asialoglycoprotein receptor has
been reported as a receptor for MARV (Becker et al., 1995).
Recently it was shown that two cellular proteases Cathpsin B
and L residing in the endosome are required for Ebola entry
(Chandran et al., 2005; Schornberg et al., 2006).
Filoviral glycoproteins, apart from their role in virus entry,
also play an important role in the pathogenicity of infection. It has
been shown that expression of EGP from plasmids or adenovirus
vectors induces cytopathic effect in cell lines and human blood
vessel explants (Simmons et al., 2002; Yang et al., 2000). This
cytopathic effect is likely caused by GP over-expression and has
been mapped to the mucin-like region present in the C-terminus
of GP1 (Alazard-Dany et al., 2006; Simmons et al., 2002; Yang
et al., 2000). EGP, when over-expressed, also causes down-
regulation of molecules involved in cell adhesion (integrins)
and immune surveillance (MHC I) (Simmons et al., 2002; Takada
et al., 2000). Virus-like particles containing EGP on the surface
activate macrophages to secrete several pro-inflammatory
cytokines (Bosio et al., 2004; Stroher et al., 2001). Recently,
Dolnik et al. (2004) showed that significant amounts of EGP in
soluble form are shed from Ebola-infected cells by proteolytic
cleavage on the cell surface by tumor necrosis factorα converting
enzyme (TACE). This shed GP has been suggested to play a role
in immune evasion by blocking neutralizing antibodies.
Previously, we have performed a comprehensive analysis of
EGP1 and identified residues important for GP1 structure/folding
and receptor binding (Manicassamy et al., 2005). Sequence
alignment of EGP1 with MGP1 suggested that most of these
critical residues are conserved between the two viruses.
However, molecular analysis of Marburg GP (MGP) has been
limited compared to EGP (Jeffers et al., 2002; Manicassamy et
al., 2005). In the current study, we analyzed MGP and identified
several regions important for GP structure and function. It was
found that MGP shares several common features with EGP.
Surprisingly, substitutions of the conserved residues in MGP1
adversely affected MGP folding and function, suggesting that
MGP folding is very distinct from that of EGP.
Results
Deletion analysis of Marburg GP
Marburg and Ebola glycoproteins share approximately 28%
amino acid identity (Sanchez et al., 1993, 1998). In contrast to
EGP, the furin cleavage site of MGP is located within themucin-like region, thus splitting the mucin-like region into GP1
and GP2 (Fig. 1) (Sanchez et al., 1998; Volchkov et al., 2000).
Previously, we and others demonstrated that the mucin-like
region of EGP can be deleted without adversely affecting the
entry function of EGP (Jeffers et al., 2002; Manicassamy et al.,
2005; Simmons et al., 2002). Here we first examined the role, if
any, of the mucin-like region of MGP in viral entry.
To perform analysis of Marburg glycoprotein (MGP), the
entire MGP-coding region was cloned into a mammalian
expression vector pEF4-myc/his, thus creating a myc epitope-
tagged MGP at the carboxyl terminus (Fig. 1, top). In addition,
two deletion mutants were generated (Fig. 1, middle) which
have the N-terminal part of the mucin-like region (within GP1
of MGP) deleted (ΔMGP1,Δ289–422) or the entire mucin-like
region deleted (ΔMGP, Δ289–501).
To examine expression, incorporation onto HIV-particles,
and infectivity, these MGP constructs were transfected
individually into 293T cells along with an HIV vector carrying
a firefly luciferase reporter gene. Western blot analysis of the wt
MGP-transfected 293T cell lysates showed two bands which
correspond to the predicted Pre-GP (about 150 kDa) and GP2
subunit (about 45 kDa) of MGP (Fig. 2A, lane 4), indicating that
MGP was expressed in 293T cells. Two myc-tagged bands
smaller than the predicted GP2, one approximately 14 kDa and
another about 25 kDa, were also detected in the 293T cell
lysates (Fig. 2A, lane 4). Surprisingly, the 14 kDa band was
even more abundant than GP2 (Fig. 2A, lane 4). Analysis of the
pellet obtained after ultracentrifugation of the culture super-
natants at 50,000 rpm showed that MGP is incorporated into
HIV particles (Fig. 2B, lane 4). The two aforementioned GP2-
specific proteins were not detected in the pelleted material.
Two MGP deletion mutants were also expressed in 293T
cells (Fig. 2A, lanes 2 and 3) and the expected bands
corresponding to GP2 (ΔMGP1) or truncated GP2 (ΔMGP,
∼28 kDa) were efficiently incorporated into HIV particles
Fig. 2. Analysis of Marburg GP ΔMucin mutants. (A) Immunoblot analysis of wild-type (WT) and mutants of MARV GP in cell lysates separated on an SDS-PAGE.
(B) Immunoblot analysis WTand GP mutants incorporated in pseudotyped virus particles (detected as GP2). HIV p24 protein was detected in the particles as a loading
control. (C) The infectivity of GP-pseudotyped particles represented as relative to WT infectivity (100%). Data represent an average of three independent experiments.
Bars, standard deviations.
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also detected in the lysates of the 293T cells transfected with
MGP mutants (Fig. 2A, lanes 3 and 4), but they were not
detected in the virions (Fig. 2B, lanes 3 and 4). These results
seem to suggest that like EGP,MGP could also be proteolytically
cleaved in the ectodomain of MGP2 (Dolnik et al., 2004).
However, further analysis is needed to identify the nature of
these GP2-specific products. In addition, unlike EGP, MGP did
not cause any visible cytopathic effects in transfected cells (data
not shown).
To examine the effect of the MGP deletions in viral entry,
HIV-particles pseudotyped with either wt MGP or the mutants
were used to challenge 293T cells as target and the luciferase
activities in the infected cells were determined as a measure of
the GP-mediated viral entry. Wt MGP/HIV-infected cells
showed a high level of luciferase activity (more than 106
relative light units, or RLUs), more than 10,000 times the
background level (about 100 RLU, Fig. 2C). Similar to wt
MGP/HIV,ΔMGP1/HIV-infected cells also showed a high level
of luciferase activity (93% of the wt MGP level), suggesting that
deletion of the mucin-like portion in MGP1 did not adversely
affect the ability of MGP to mediate viral entry. The level of
luciferase activity in ΔMGP/HIV-infected cells was approxi-
mately 1/3 of the wt MGP/HIV-infected cells (Fig. 2C). This
reduction is most likely due to the lower level of incorporation
of ΔMGP into HIV virions compared to wt MGP or ΔMGP1
(see Fig. 2B), even though expression of this mutant in the cells
was higher than that of the wt MGP or ΔMGP1 (see Fig. 2A).
To further analyze if the reduction in infectivity of ΔMGP
was due to an additive effect of the deletions in both MGP1 and
MGP2 or if it was caused by deletion in MGP2 alone, an
additional furin cleavage site was introduced between residues496–499 (PNIN to RRKR) of MGP, thus the mucin-like portion
in MGP2 can be removed by furin cleavage during MGP
processing (see Fig. 1, top). This mutant also displayed reduced
level of infectivity (∼40% of wt MGP level, data not shown),
suggesting that the decrease in infectivity is due to the deletion
of the mucin-like portion in MGP2 alone.
Together, these results suggest that like EGP, the mucin-like
regions of MGP do not play a major role in mediating viral entry
(Jeffers et al., 2002; Manicassamy et al., 2005). In contrast to
EGP, however, deletion of the mucin-like regions in MGP did
not enhance viral entry.
Analysis of amino acid substitutions for function of MGP
Previously, we reported a comprehensive alanine substitu-
tion study on EGP in protein folding and viral entry, and a
number of key residues involved in protein folding and viral
entry have been identified (Manicassamy et al., 2005).
Sequence alignment of EGP and MGP indicated that most of
the key residues are conserved between Ebola and Marburg,
suggesting that EGP and MGP have a similar structure and they
use the same or related receptors in viral entry. In this study, we
targeted 16 conserved and 9 non-conserved residues in MGP1
by substitution mutations (Fig. 3), and each of the mutants was
examined in protein expression, processing, incorporation into
HIV virions, and viral entry.
Conserved residues
To target the 16 conserved residues ofMGP1 shown in Fig. 3,
18 substitution mutants were generated (Fig. 4). The Pre-GPer
form was detected in the lysates of 293T cells transiently
transfected by the mutants (Fig. 4A and C). However, levels of
Fig. 3. Sequence alignment comparison of Zaire EBOV GP and Lake victoriaMARV GP. Residues targeted for mutation are indicated by triangle. Identical residues
are indicated by closed triangle (▾) and other residues are indicated by open triangle (∇).
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V47, H48, K68, R69, F72, H123, H124, D147, D147/R148),
and thus little or no GP2 was detected on the HIV-particles (Fig.
4A, lanes 2, 3, 5, 6, 7, 8, and C, lanes 3, 4, 5, and 6).
Consequently, these mutants were unable to mediate MGP/HIV
infection to the 293T cells (Fig. 4B and D). We conclude that
these substitutions abrogated the correct folding of MGP. In
contrast, three mutants (K118A/K120A, M154A, R156A) did
not display any detectable defects in protein expression,
incorporation into virus-particles, or viral entry, suggesting
that these residues are not critical in MGP folding or viral entry.
Finally, two mutants (R73A, and K79A) did not show major
defects in protein expression or viral incorporation, but they
were defective in mediating viral infection (Fig. 4), suggesting
that these residues may be directly involved in viral entry.
Together, our results show that many of the residues conserved
between EBOVand MARVare important in maintaining proper
folding/structure of MGP. It appears that, compared to that ofEGP, substitutions in MGP disrupt the correct folding and
structure of the protein even more drastically when compared
with EGP (Manicassamy et al., 2005).
Non-conserved residues
We next sought to examine whether substitutions of the non
(or less)-conserved residues in MGP also adversely affected
correct protein folding and viral entry. Nine alanine substitution
mutants were generated (E45, D108, R114, D115, Q126, K172,
K176, K230, D262). All of the mutants were expressed in 293T
cells, and the mutant MGPs were incorporated into the HIV
virions at levels comparable to that of wt MGP (Fig. 5A). It was
found that all of the mutant MGPs except R114A were able
to mediate viral entry at levels of 50% or more of wt MGP
(Fig. 5B). These results indicate that these non-conserved
residues do not play a critical role in MGP folding or function,
which is in stark contrast with the results of the conserved
residues described above.
Fig. 4. Alanine substitution analysis of the MARVGP. (A and C) Glycoprotein expression and incorporation into pseudoparticles. (B and D) Infectivity of pseudotyped
particles. Data represent the average of three independent experiments. Bars, standard deviations.
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Fig. 5. Alanine substitution analysis of the non-conserved residues in Marburg GP. (A) Glycoprotein expression and incorporation in virion. (B) Infectivity of
pseudotyped virus. Data represent an average of three independent experiments. Bars, standard deviations.
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To test whether Marburg and Ebola viruses use the same or
related molecules as receptors for viral entry, we developed an
entry interference assay for filoviruses. This assay is based on
the assumption that if Ebola and Marburg viruses use the same
or related molecules in viral entry, expression of EGP in the
target cells should interfere with entry by the MGP/HIV and
vice versa.
First, 293T cells were transiently transfected with various
amounts of eitherΔEGP (mucin-like region deleted, see Fig. 1),
or control vectors: an empty vector (pcDNA3.1) or EnvA (the
glycoprotein for subgroup A avian sarcoma and leukosis virus,
or ASLV-A). ΔEGP instead of wt EGP was used in these
experiments because over-expression of wt EGP in 293T cells
can cause cell rounding and detachment, while expression of
ΔEGP in the cells does not exert detectable cytopathic effects
(Manicassamy et al., 2005; Simmons et al., 2002; Yang et al.,
2000). Further, deletion of the mucin-like region in EGP does
not adversely affect its ability to mediate efficient viral entry
(Jeffers et al., 2002; Manicassamy et al., 2005). As shown in
Fig. 6A, luciferase levels of the target cells challenged with the
EGP/HIV pseudotyped viruses were inversely correlated with
the amounts ofΔEGP DNA used in the transfection. When 4 μg
of ΔEGP DNAwas used in the assay, the luciferase level of the
target cells dropped by more than 60% compared to the control
(empty vector). Further,ΔEGP did not adversely affect entry by
VSV-G/HIV pseudovirions, demonstrating the specificity of the
entry interference by EGP. Interestingly, transfection of ΔEGP
could interfere entry by the MGP/HIV virions to the target cells
also in a dose-dependent manner, similar to the results with the
EGP/HIV virions (Fig. 6A). Transfection of EnvA plasmid did
not have any effect on EGP/, MGP/, or VSV-G/HIV virions
(data not shown), further demonstrating specificity in entry
interference.Next, we examined whether the observed entry interference
was reciprocal between EGP and MGP. Transfection of 293T
cells with either ΔMGP (Fig. 6B) or ΔMGP1 (Fig. 6C) could
interfere with infection by the EGP/HIVor MGP/HIV viruses in
a dose-dependent manner. Together, these results suggest that
Ebola and Marburg viruses use same or related modules in viral
entry.
Discussion
Molecular analysis of the Marburg GP (MGP) in viral entry,
up to date, has been very limited compared to that of Ebola GP
(EGP) (Jeffers et al., 2002; Manicassamy et al., 2005; Simmons
et al., 2002). In the current study, we characterized the roles of
the different regions and individual residues of MGP in protein
folding and viral entry and we demonstrate that MGP and EGP,
although displaying a high degree of sequence variations, share
several common features. First, the mucin-like region in MGP,
like that in EGP, is not critical for the entry function of MGP
(Jeffers et al., 2002; Manicassamy et al., 2005). These results
strongly suggest that viral entry function is mediated by the
N-terminal region of MGP1 (likely the receptor-binding
domain, referred to as RBD), and the C-terminal region of
MGP2 (the domain mediating membrane fusion). Second,
substitutions of the non-conserved residues in the putative
receptor-interaction domain of MGP1 did not adversely affect
MGP folding or its ability to mediate viral entry. Third,
reciprocal interference of EGP and MGP in viral entry supports
the hypothesis that Marburg and Ebola viruses share the same or
related molecules as the cellular receptor (Kuhn et al., 2006;
Manicassamy et al., 2005).
Sequence comparison between MGP and EGP indicates that
the N-terminal region (residues 1–200) and the C-terminal
region (residues 500–676) are more conserved with approxi-
mately 50% identity than the central portion including the so-
Fig. 6. Viral entry interference by GP. 293T cells were transfected with varying
amounts of GP plasmids (4 μg total). After 48 h, the cells were dissociated and
seeded into 6-well plates (4×105 cells/well) in 0.75 ml fresh media.
Immediately, 0.5 ml of different pseudotyped viruses was added and mixed.
After 48 h p.i., the cells were lysed and luciferase activity was measured. The
luciferase activities are represented as relative to control vector transfected cells.
(A) Pseudotyped virus entry in cells expressing ΔEGP. (B) Pseudotyped virus
entry in cells expressingΔMGP. (C) Pseudotyped virus entry in cells expressing
ΔMGP1. Data represent the average of three independent experiments.
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described in Results, unlike the mucin-like region of EGP, the
mucin-like region of MGP is split into MGP1 and MGP2 after
furin cleavage (see Fig. 1). Deletion of the mucin-like region of
EGP does not adversely affect the viral entry function of EGP,
rather, it enhances the ability of EGP to mediate viral entry
(about 3-fold of wt EGP) in tissue cultures (Jeffers et al., 2002;
Manicassamy et al., 2005). Here we show that deletion of the
mucin-like region did not drastically reduce the viral entry
function of MGP. In contrary to EGP, deletion of the mucin-like
region of MGP did not enhance the ability of MGP in mediating
viral entry. This difference is likely due to the fact that deletion
of this region in MGP appears to be correlated with lower levels
of MGP incorporation into HIV virions (see Fig. 2), while
deletion of the mucin-like region of EGP seems to enhance the
level of EGP incorporation into HIV virions (Jeffers et al., 2002;Manicassamy et al., 2005). It is important to point out that
although the mucin-like region is not required for MGP/HIV
pseudotyped viral entry, it may still play an important role in
viral infection and pathogenesis. Several in vitro studies suggest
that the mucin-like region (residues 300–500) is essential for
viral attachment to C-type lectins DC-SIGN, DC-SIGN(R), and
hMGL which are highly expressed in macrophages and
dendritic cells and thus enhance viral infection (Alvarez et al.,
2002; Marzi et al., 2004; Simmons et al., 2003a; Takada et al.,
2004). Since Ebola and Marburg viruses are shown to have
preferential tropism for macrophages and dendritic cells during
early stages of infection, it is possible that the mucin-like region
of MGP (and EGP) is one of the contributing factors for the
preferential tropism to macrophage/dendritic cells (Bray and
Geisbert, 2005; Sanchez et al., 2001).
Identification of the cellular receptor(s) for Ebola and
Marburg viruses has been elusive. Although folate receptor
(α) was postulated as the cellular receptor for both Ebola and
Marburg viruses in one study, the validity of this claim was
challenged by the results from another group (Chan et al., 2001;
Simmons et al., 2003b). The previous work on EGP by us has
mapped the putative region involved in receptor-interaction
(RBD) to the N-terminal 150 residues of GP1 which is
confirmed by a recent study by another group (Kuhn et al.,
2006; Manicassamy et al., 2005). Further, our results suggest
that Ebola and Marburg use the same or related molecules for
viral entry. The reciprocal interference by EGP and MGP on
viral entry presented in this study is consistent with this notion.
It has been repeatedly demonstrated that viral infection can
lead to viral receptor down-regulation in the infected cells
(Klucking et al., 2002; Martin and Nayak, 1996; Nethe et al.,
2005; Weiss, 1993). Hence the infected cells become resistant to
superinfection by the same virus or viruses which use the same
receptor for infection. It has been observed that, in these
infected cells, newly synthesized viral glycoproteins can form
intracellular complexes with the viral receptor and the
complexes are retained inside the cells. Since the identity of
the receptor for either Ebola or Marburg viruses is still
unknown, we have developed a filoviral entry interference
assay modified from classic protocols. This assay relies on
using GP/HIV pseudotyped virions to challenge the target cells
(293T) expressing GP by transient transfection. As shown in
Fig. 6, transfection of an Ebola GP plasmid into 293T cells can
significantly inhibit entry of the EGP/HIVor MGP/HIV virions
in a specific dose-dependent manner and vice versa. These data
are in agreement with the notion that EBOVand MARV use the
same or related surface molecules as the receptor. It should be
noted that we did not achieve a complete inhibition under the
experimental conditions (up to approximately 70% inhibition),
which is probably limited by transfection efficiencies in these
experiments (we can routinely achieve approximately 50–80%
transfection efficiency for 293T cells). Thus higher levels of
inhibition are expected when the target cells stably expressing
glycoproteins are challenged by the pseudotyped HIV virions in
these experiments. Indeed, 293T cells stably expressing ΔEGP
by retroviral transduction displayed more than 90% of
inhibition on EGP-mediated viral entry (J. W. and L. R.,
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MGP on viral entry reported in this study further suggests that
these viruses may use the same molecule as the receptor, as
proposed by us and others (Kuhn et al., 2006; Manicassamy et
al., 2005). We believe that if Marburg and Ebola viruses indeed
use the same receptor for viral entry, it is possible to develop
pan-entry inhibitors to block viral infection and pathogenesis
for both Ebola and Marburg viruses in the future.
An unexpected observation in this study is that comparison
of the MGP mutants and the corresponding mutants of EGP in
the previous study suggest differences in their protein folding
(Table 1) (Manicassamy et al., 2005). Only three of the
conserved residue mutants of MGP (K79A, K118A/K120A,
and R156A) showed phenotypes similar to that of EGP mutants
(K95A, R134A/R136A, and R172A) while the rest of the MGP
mutants, unlike that of EGP, displayed defects in protein
folding. It is possible that these differences in protein folding are
in part due to the different disulfide bonding pattern in Ebola
and Marburg GP1s. Ebola GP1 contains two disulfide bonds in
the putative RBD formed by alternate cysteines (C108/C135
and C121/C147), whereas Marburg GP probably contains one
disulfide bond in the putative RBD (C92/C119) and one outside
of the RBD formed by consecutive cysteines (C212/C226)
(Jeffers et al., 2002). Mutation of C121/C147 in Ebola GP (not
conserved in Marburg GP1) does not affect Ebola virus entry,
but disulfide bonds can increase the stability by restricting free
movement in the protein (lower entropy; Jeffers et al., 2002). It
is likely that in Ebola GP1, the additional disulfide bond in the
RBD restricts major structural alteration and hence Ebola GP is
more tolerant to most of the alanine substitutions. Another
possibility is that the differences in the phenotypes of mutants inTable 1
Comparison of the mutant phenotypes of the conserved residues in Ebola and Marb
Ebola GP M
Mutant Expression Incorporation Infectivity (% of wt) Class M
L57A + + + + + + + 21 IV L
L63A + + + + + + + + 14 IV V
R64A + + + + + + + + 0 IV H
R64K + + + + + + + + 120 n/a H
R64E + + + + + + + 0 n/a H
K84A + + + + + + + + 94 I K
R85A + + 0 II R
F88A + + + + + + + + 1 IV F
R89A + + + + + + + 59 I R
K95A + + + + + + + + 8 IV K
R134A/R136A + + + + + + 59 III K
H139A + + 2 II H
K140A + + + + + + + + 74 I H
D163 n/d n/d n/d n/d D
D163A/R164A + + + + + + + 58 I D
I170A + + + + + + + + 16 IV M
R172A + + + + + + + + 55 I R
Class I—no major defect in protein expression/processing, virion incorporation, or
Class II—defective in protein expression/processing.
Class III—defective in virion incorporation.
Class IV—defective in viral entry.
The mutants were classified as previously described (Manicassamy et al., 2005).
n/d—not determined.
n/a—not applicable.Marburg GP may reflect differences in the overall folding of
GP1. Elucidation of these differences in protein folding of MGP
and EGP may provide insightful information on structure and
function of filoviral glycoproteins.
Materials and methods
Cell lines and antibodies
Human embryonic kidney cells (293T) were grown in
Dulbecco's modified Eagles medium (DMEM) supplemented
with 10% fetal bovine serum (Gibco) and penicillin/streptomy-
cin (100 U/ml). Anti-p24 monoclonal antibody was obtained
from National Institutes of Health AIDS Research and
Reference Reagent Program (Simon et al., 1997). Anti-myc
(9E10) and anti-mouse HRP were purchased from Sigma (St.
Louis).
Mutagenesis
Plasmid vectors expressing GP of Zaire Ebola virus (EGP)
and mucin-deletion mutant (ΔEGP) were described earlier
(Manicassamy et al., 2005). Marburg GP (Lake Victoria strain)
was PCR cloned from phCMV1 vector into pEF4-myc/his A
vector (Invitrogen) for easy detection in Western blotting with
anti-myc antibodies (9E10 clone). Marburg GP mucin-deletion
mutants (ΔMGP1 and ΔMGP) were generated by two-step
PCR and cloned into pEF4-myc/hisA vector. All mutants of the
Marburg GP gene were generated by site-directed mutagenesis
with the Stratagene QuickChange Site-directed mutagenesis kit
according to the supplier's protocols. The mutations wereurg GPs
arburg GP
utant Expression Incorporation Infectivity (% of wt) Class
41A + + + + ++ 0 III
47A + − 0 II
48A + + + 0 II
48R + + + + + + + + 103 n/a
48E + + +/− 0 n/a
68A + + + + 0.08 II
69A + + +/− 0 II
72A + + +/− 0 II
73A + + + + + + + 0.06 IV
79A + + + + + + 4.3 IV
118A/K120A + + + + + + + + 124 I
123A + + +/− 0 II
124A + + − 0 II
147A + + − 0 II
147A/R148A + + − 0 II
154A + + + + + + + 99 I
156A + + + + + + + 106 I
viral entry (wild type phenotype).
87B. Manicassamy et al. / Virology 358 (2007) 79–88confirmed by DNA sequencing of flanking regions (CRC-
sequencing facility, University of Chicago; on average approxi-
mately 800 bp).
Pseudotyping
Pseudotyped viruses were produced by co-transfecting 2 μg
of wild-type (wt) MGP or mutants with 2 μg Env-deficient HIV
vector (pNL4-3-Luc-R−-E−) into 293T cells (90% confluent) in
six-well plates with Lipofectamine 2000 according to the
protocol of the supplier (Invitrogen) (Connor et al., 1995; He et
al., 1995). The supernatants containing the pseudotyped viruses
were collected twice (at 24 and 48 h post-transfection),
combined, clarified from floating cells and cells debris by
low-speed centrifugation, and filtered through a 0.45 μm pore-
size filter (Nalgene). The viruses were immediately used to
infect target cells.
Western blotting
To evaluate MGP expression, the 293T producer cells were
lysed 48 h post transfection in 300 μl of Triton X-100 lysis
buffer (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA,
1% Triton X-100, and a protease inhibitors cocktail consisting
of 10 μg/ml of leupeptin, 5 μg/ml of aprotinin, and 2 mM
phenylmethylsulfonyl fluoride). The protein samples were
subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred to a polyvinyli-
dene difluoride membrane. The membrane was first incubated
with 9E10 monoclonal antibody (1:2500 dilution) for 2 h and
then probed with HRP-conjugated goat anti-mouse antiserum
(1:10,000 dilution) for 30 min. The bands were visualized by
the chemiluminescence method according to the protocol of the
supplier (Pierce). To evaluate the incorporation of wt GPs
protein or mutants into the pseudotyped viruses, 4 ml of
pseudotyped viruses was layered onto a 1-ml cushion of 20%
(wt/vol) sucrose in phosphate-buffered saline and centrifuged at
55,000 rpm for 40 min in a Beckman SW55 rotor. The virus
pellets were lysed in 100 μl of Triton X-100 lysis buffer, and a
30 μl sample was subjected to SDS-PAGE. Incorporation of wt
or mutants MGP into HIV virions was detected by Western
blotting as described above. A mouse anti-HIV p24 monoclonal
antibody (1:5000 dilution) was used to detect the HIV p24
protein level.
Infectivity assay
293T cells (1×105) were seeded in 12-well plates. The next
day, 0.25 ml of pseudotyped viruses was added to the cells.
After 12 h incubation, the media was replaced with 1 ml of fresh
media. The cells were lysed in 250 μl cell culture lysis reagent
(Promega) at 48 h post-infection (p.i.) and the luciferase
activities in the cell lysates were measured with a luciferase
assay kit (Promega) using a FB12 luminometer (Berthold
detection systems). The luciferase activity in each sample was
measured in duplicate and the experiments were repeated at
least three times.Entry interference assay
Production of pseudotyped viruses
Virus entry interference assays were done using 293T cells
transiently expressing various GPs as target cells. To produce
HIV/GP pseudovirions for the assay, a three-plasmid-based
system instead of the aforementioned two-plasmid system was
used to produce pseudotyped virions (Naldini et al., 1996). In
this system, the structural proteins (gag-pol) were provided in
trans with the luciferase reporter gene expression vector
carrying HIV RNA packaging signal. The pseudotyped virions
should only have the reporter gene packaged as the viral
genome and thus cannot generate new HIV/GP virions in the
target cells. Briefly, 293T cells were co-transfected with 2.4 μg
of HR'-CMV-Luc (luciferase reporter), 1 μg of Δ8.2 (gag-pol),
and 0.3 μg of EGP or MGP or VSV-G plasmids using Lipo-
fectamine 2000 as described earlier.
Interference assay
The day prior to transfection, 293T cells were seeded in 6-
well (8×105 cells per well) plates coated with poly-L-lysine
(Sigma). The next day, cells were transfected with varying
amounts (0, 0.25, 0.5, 1, 2, 4 μg) of expression plasmid (ΔEGP
or ΔMGP1 or ΔMGP) using Lipofectamine 2000 following
supplier's protocol. In all transfections, the total amount of DNA
was kept at 4 μg by adding the control vector (pCDNA3.1 or
pEF4-myc/his). After 5 h, the transfectionmix was replaced with
3 ml fresh media. At 48 h, the cells were washed once with PBS
and dissociated from the plate using Hank-based cell dissocia-
tion buffer (Gibco). The cells in 0.75 ml of fresh media were
seeded into 6-well plates (approximately 4×105 cells per well).
Pseudotyped viruses (HR'-CMV-Luc) were immediately added
(0.5 ml) to each well and mixed. Eight hours p.i., the viruses
were removed and 2ml of fresh media was added. The cells were
lysed in 500 μl of lysis reagent (Promega) at 48 h p.i. The
luciferase activities of the target cells were measured with a
luciferase assay kit (Promega) and an FB12 luminometer
(Berthold detection system) according to the supplier's protocol.
The luciferase activity in each sample was measured in
triplicates and the experiments were repeated at least three times.
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